A Close Look at Baxter International’s Acquisitions
Sales from Baxter International’s (BAX) Acute Therapies rose 22%, from $106 million in Q1 2017 to $129 million in Q1 2018 on the back of higher demand for Baxter’s CRRT (continuous renal replacement therapies) systems. In July 2017, Baxter International acquired Claris Lifesciences’ subsidiary Claris Injectables for a cash consideration of $629 million. Through this acquisition, Baxter gained capabilities in the production of essential generic injectable medicines such as anesthesia and analgesics, renal, anti-infectives, and critical care in bags, vials, and ampoules.